Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (PACTR202508611698393) titled 'A Phase I/II study of ITU512 in healthy participants and patients with sickle cell disease' on Aug. 1.

Study Type: Interventional

Study Design: Parallel: different groups receive different interventions at same time during study,Randomised,Permuted block randomization,Central randomisation by phone/fax

Primary Sponsor: Novartis Pharmaceuticals

Condition:

Haematological Disorders

Recruitment Status: Recruiting

Phase: Phase-1

Date of First Enrollment: 15/08/2024

Target Sample Size: 161

Countries of Recruitment: Ghana Ghana Kenya Kenya Kenya Uganda

To know more, visit https://pactr.samrc.ac.za/Tr...